Safety, PK, and Food Effect of BI 3031185 in Healthy Men

Phase 1, randomised, single-blind trial of BI 3031185 in borderline personality disorder (BPD) and attention deficit hyperactivity disorder (ADHD) (11 arms), sponsored by Boehringer Ingelheim. Primary endpoints: The occurrence of any treatment-emergent adverse event (AE) assessed as drug-related by the investigator up to 22 days, Area under the concentration-time curve of the analyte in plasma over the dosing interval 0 to 24 hours and 1 more. Started Mar 2024; status: completed.